CSL Recognized as One of Montreal's Top Employers for Seventh Consecutive Year
CSL recognized as one of Montreal's Top Employers for seventh consecutive year
MONTREAL, March 18, 2025 (GLOBE NEWSWIRE) -- The CSL Group ('CSL'), a global leader in responsible marine transportation, is excited to announce it has been named one of Montreal's Top Employers for the seventh year in a row. This achievement follows CSL's earlier acknowledgment as one of Canada's Top Employers for Young People for the fourth year running, underscoring CSL's ongoing commitment to nurturing talent and fostering employee growth and satisfaction.
'We owe this recognition to the dedication and hard work of every CSLer,' said Stéphanie Aubourg, Chief Human Resources Officer at CSL. 'Our success is built on a culture of diversity and collaboration, where employees at all levels are empowered and supported to reach their full potential. We value the unique perspectives that each team member brings, and it's their commitment that drives us forward.'
CSL fosters an inclusive and dynamic workplace with a focus on employee well-being, offering flexible work arrangements, comprehensive health programs, and professional development and training opportunities. The company's commitment to sustainability and community engagement further strengthens employees' sense of purpose and pride in their work.
'If you're looking for a challenging, innovative environment where you can make a real impact, CSL is the place for you,' added Aubourg. 'We offer exciting projects and global opportunities for individuals ready to contribute to the future of marine transportation.'
Montreal's Top Employers is an annual competition organized by Mediacorp Canada Inc., recognizing companies in the Montreal area that stand out among their industry peers by providing exceptional workplaces.
is a world class provider of complex marine solutions and the largest owner and operator of self-unloading ships in the world. Headquartered in Montreal with operations throughout the Americas, Australia, Europe and Africa, CSL provides a broad range of shipping and handling services and delivers millions of tonnes of cargo annually for customers in the construction, steel, energy and agri-food sectors.
Media Contact: Brigitte Hébert, Director, Communications514-653-8854| brigitte.hebert@cslships.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d721e48f-2396-4d7e-999b-19c4d4be8289
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Merus N.V. Announces Pricing of Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) ('Merus', the 'Company,' 'we' and 'our'), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the pricing of an underwritten public offering of 5,263,158 common shares, at a public offering price of $57.00 per share (the 'Offer Shares'). Merus also granted the underwriters a 30-day option to purchase up to an additional 789,473 common shares (the 'Option Shares' and together with the Offer Shares, the 'Shares'). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters' option to purchase the Option Shares, are expected to be approximately $300.0 million. All of the shares in the offering are to be sold by Merus. The offering is expected to close on or about June 5, 2025, subject to customary closing conditions. Merus currently intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to advance the clinical development of its product candidates, for preclinical research and technology development, and for working capital and general corporate purposes. Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities, Truist Securities, and LifeSci Capital are acting as joint book-running managers for the offering. Van Lanschot Kempen is acting as lead manager for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission ('SEC') on February 28, 2024 and was effective upon filing. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement, which, for the avoidance of doubt, will not constitute a 'prospectus' for the purposes of (i) Regulation (EU) 2017/1129 (the 'Prospectus Regulation') and has not been reviewed by any competent authority in any member state in the European Economic Area (the 'EEA') and (ii) the Prospectus Regulation as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (the 'UK Prospectus Regulation') and has not been reviewed by the Financial Conduct Authority in the United Kingdom. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on June 3, 2025, and a final prospectus supplement will be filed with the SEC and will be available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@ BofA Securities NC1-0220-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, NC 28255‐0001, or by email at Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@ Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@ or Truist Securities, Inc., Attention: Equity Capital Markets, 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326 at (800) 685-4786 or by email to This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is an advertisement and not a prospectus within the meaning of either the Prospectus Regulation or the UK Prospectus Regulation. EEA: In relation to each member state of the EEA (each, a 'Relevant State'), no Shares have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the Shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that Shares may be offered to the public in that Relevant State at any time: to any legal entity which is a 'qualified investor' as defined under Article 2 of the Prospectus Regulation; to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; and in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of the Shares shall require us or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. Each person who initially acquires any Shares or to whom any offer is made will be deemed to have represented, warranted, acknowledged and agreed to and with us and each of the underwriters that it is a 'qualified investor' within the meaning of Article 2 of the Prospectus Regulation. For the purposes of the above, the expression 'offer to the public' in relation to the Shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any Shares to be offered so as to enable an investor to decide to purchase or subscribe for any Shares, and the expression 'Prospectus Regulation' means Regulation (EU) 2017/1129. United Kingdom: No Shares have been offered or will be offered pursuant to this offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the Shares which has been approved by the Financial Conduct Authority in the United Kingdom, except that the Shares may be offered to the public in the United Kingdom at any time: a) to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation; b) to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or c) in any other circumstances falling within Section 86 of the Financial Services and Markets Act 2000 (the 'FSMA'), provided that no such offer of the Shares shall require us or any of the underwriters to publish a prospectus pursuant to Section 85 of the FSMA or Article 3 of the UK Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. Each person in the United Kingdom who initially acquires any Shares or to whom any offer is made will be deemed to have represented, warranted, acknowledged and agreed to and with us and each of the underwriters that it is a 'qualified investor' within the meaning of the UK Prospectus Regulation. For the purposes of this provision, the expression an 'offer to the public' in relation to the Shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any Shares to be offered so as to enable an investor to decide to purchase or subscribe for any Shares. In addition, in the United Kingdom, the transaction to which this press release relates will only be available to, and will be engaged in only with persons who are 'qualified investors' (as defined in the UK Prospectus Regulation) (i) who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005, as amended (the Order), and/or (ii) who are high net worth entities (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as 'relevant persons'). In the United Kingdom, the securities referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with relevant persons. Any person in the United Kingdom who is not a relevant person should not act or rely on this communication or any of its contents. About Merus N.V. Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding the completion of the proposed offering, the anticipated gross proceeds from the offering and our intended use of any net proceeds from the offering. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics®, Triclonics® and multispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; impacts of the global instability caused by the Russia Ukraine conflict and conflict in the Middle East; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaborations or our collaborators may fail to perform adequately under our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. These and other important factors discussed under the caption 'Risk Factors' in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the Securities and Exchange Commission, or SEC, on May 7, 2025, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Multiclonics®, ADClonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V. CONTACT: Investor and Media Inquiries: Sherri Spear Merus N.V. SVP Investor Relations and Strategic Communications 617-821-3246 Kathleen Farren Merus N.V. Director Investor Relations and Corporate Communications 617-230-4165
Yahoo
2 hours ago
- Yahoo
AVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards
VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced that RECELLⓇ, including RECELLⓇ GO, has been recognized as the 'Best New Technology Solution – Surgical' in the 2025 MedTech Breakthrough Awards. RECELL, FDA-approved for thermal burn wounds and full-thickness skin defects, has treated over 30,000 patients worldwide. RECELL requires significantly less donor skin than traditional grafting, reducing donor-site pain and accelerating recovery. Additional clinical outcomes include fewer procedures, improved functional and aesthetic results, and shorter hospital stays. RECELL GO retains these clinical benefits while enhancing procedural consistency and surgical team coordination, with the physician remaining central throughout the procedure. This design supports adoption in high-volume burn and trauma centers, and enables scalable, cost-efficient deployment across acute wound care settings. 'We appreciate this recognition, which highlights RECELL's advantages in burn and trauma care,' said Jim Corbett, Chief Executive Officer of AVITA Medical. 'By requiring significantly less donor skin than traditional grafting, RECELL reduces donor-site pain, accelerates healing and improves patient outcomes. We remain committed to expanding access and advancing care for patients.' The MedTech Breakthrough Awards honor companies and products shaping healthcare's future. The 2025 program drew over 4,500 nominations globally. In addition to this recognition, Dr. Katie Bush, Senior Vice President of Scientific & Medical Affairs of AVITA Medical, was awarded the 2025 Emerald Pinnacle Healthcare Award in the Medical Device category. The Pinnacle Award celebrates companies and individuals who have demonstrated exceptional innovation, leadership, and impact in healthcare. About AVITA Medical, Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL System®, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient's own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point of care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix. In international markets, the RECELL System is approved to promote skin healing in a wide range of applications, including burns, full-thickness skin defects, and vitiligo. The RECELL System, excluding RECELL GO™, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan. To learn more, visit Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'future,' 'goal,' 'guidance,' 'intend,' 'look forward,' 'may,' 'outlook,' 'project,' 'target,' 'will,' 'would,' and similar words or expressions, and the use of future dates. Forward-looking statements include, but are not limited to, statements relating to the timing and realization of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company's control. These statements are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the 'Risk Factors' section of the Company's latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties. Authorized for release by the Chief Financial Officer of AVITA Medical, Inc. CONTACT: Investor & Media Contact: Jessica Ekeberg investor@ media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Wingstop Taps QSIC to Power the In-Store Music for First Location in Australia
The global restaurant brand partners with QSIC to set the tone for its highly anticipated Sydney debut with a curated, brand-first audio experience MELBOURNE, Australia, June 04, 2025 (GLOBE NEWSWIRE) -- QSIC, the global in-store audio platform that uses AI audio and data intelligence to help retailers and brands unlock the value of the in-store experience, today announced it will power the in-store audio for Wingstop's first Australian location in Sydney. Wingstop has been gaining momentum on social media in Australia for months, building anticipation with fans well ahead of the official grand opening. QSIC develops audio experiences for global retailers designed to improve customer experiences, enhance sales and encourage repeat business with carefully curated music. For Wingstop's new location, QSIC's intelligent audio platform will power a branded music experience that mirrors Wingstop's bold personality and high-energy atmosphere. 'At Wingstop, we're committed to creating a world-class guest experience from our flavours to the atmosphere,' said Locky Paech, Corporate Operations Director at Wingstop. 'As we opened our first location in Australia, we wanted every detail to reflect the bold and energetic personality of our brand. Partnering with QSIC allows us to bring the Wingstop brand to life through music, creating a vibe that's distinctly ours from the moment guests walk through the door.' Wingstop is one of the fastest-growing global restaurant brands with more than 2,500 locations across the United States, Mexico, Canada, Singapore, the United Kingdom, France and the United Arab Emirates. Known for its bold chicken wing flavours, Wingstop has built a loyal fan base worldwide. For its new Sydney location, QSIC designed a custom audio experience that serves as an extension of the brand's bold identity. 'Curated music experiences have a significant impact on customer engagement and satisfaction,' said Brad Montgomery, QSIC's Commercial Lead APAC. 'Customers want to hear music that complements a store and enhances their experience, not just today's top hits or elevator music. With Wingstop, we're building an audio experience that's as bold and intentional as the brand itself.' QSIC powers the audio for grocery, convenience, QSR, hospitality, fashion and specialty retail locations across the globe. The company was founded in Australia and has since expanded internationally, working with leaders such as McDonald's, Coles/Reddy Express and 7-Eleven, among others. To learn more about QSIC's in-store offerings, please visit About QSICQSIC is the global intelligent in-store audio platform that uses data & AI to remove friction from the planning process and elevate and measure the impact of audio. Reaching over 100 million in-store shoppers monthly, QSIC helps retailers activate their Retail Media Networks by setting up, running and commercializing their audio assets. This extends from music curation, ad production and collateral to ad sales and price evaluation. QSIC has invested heavily in developing a patented method of measuring the impact of audio advertising on real-world in-store transactions. It is now a leading provider of AI technology that strategically leverages the power of audio to deliver better customer and sales experiences. Learn more at Media Contact for QSIC: SamsonPR QSIC@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
